10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New Collaborations

Resumen detallado
Collaborations with Charité and DRFZ, and with Seoul National University, aim to identify biomarkers of disease activity and treatment response using 10x's Flex Apex platform…
Collaborations with Charité and DRFZ, and with Seoul National University, aim to identify biomarkers of disease activity and treatment response using 10x's Flex Apex platform
PLEASANTON, Calif., Nov. 16, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced two new research collaborations focused on identifying blood-based biomarkers of disease activity and treatment response for autoimmune disease. The first collaboration is with Charité – Universitätsmedizin Berlin, one of Europe's largest university hospitals, and the German Rheumatology Research Center Berlin (DRFZ). The second is with the Genomic Medicine Institute at Seoul National University (SNU), one of South Korea's leading research universities.
Earlier this year, 10x outlined its clinical strategy for realizing the potential of single cell and spatial technologies in diagnostics, with a focus on oncology and autoimmune disease. These two new collaborations expand 10x's autoimmune disease research to Europe and Asia. Both collaborations plan to use Flex Apex to analyze longitudinal blood samples at single cell resolution. By pairing these profiles with clinical data, researchers aim to identify biomarkers of disease activity and treatment response.
"Clinical decision-making in autoimmune disease depends on symptoms and tests that provide only indirect measures of underlying immune activity, while treatment selection relies on trial and error," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "By studying longitudinal cohorts across diseases, therapies and geographies, these collaborations can help identify robust, reproducible biomarkers of disease activity and treatment response.
Charité and DRFZ: Disease Activity and Treatment Response in Rheumatoid Arthritis, Lupus and Psoriatic Arthritis
10x, Charité and DRFZ plan to conduct a multi-year study involving 750 patients with rheumatoid…
Using…
Inicio del artículo, extracto de PR Newswire. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.prnewswire.com)
